Since CD38 is expressed on haematopoietic stem cells, awareness of the long half-life of daratumumab has led researchers to question the applicability of the drug for bridging to HSCT but data to date on the use of daratumumab prior to HSCT in multiple myeloma do not indicate reduced engraftment rates (66). This evidence concerns the gene CD38 and plasma cell myeloma.